A single dose of 10-80 mg was tested in healthy males for changes in vital signs, ECG or laboratory safety parameters, and researchers found no changes. The drug performed well when looking at absorption and distribution in the body and showed the potential for once daily oral administration. The drug was designed to work similarly to other anti-neuropathic drugs without the common adverse effects.
Related Articles on Pain Management:
Stanford, UCSF to Test Ultrasound for Relieving Cancer Pain
Fibronectin Injection After Spinal Cord Injury Can Relieve Pain
DSM Collaborates with AdeTherapeutics to Develop Pain Management and Scar Reduction Product for Spine Surgeries
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.